(Q51134840)

30 March 2018

title

Socioeconomic burden of amyotrophic lateral sclerosis, myasthenia gravis and facioscapulohumeral muscular dystrophy. (English)

1 reference

30 March 2018

facioscapulohumeral muscular dystrophy

main subject

0 references

myasthenia gravis

0 references

amyotrophic lateral sclerosis

0 references

1 reference

12

Wolfgang H Oertel

1 reference

30 March 2018

9

Veit Mylius

1 reference

30 March 2018

Karsten Schepelmann

1

object named as

Karsten Schepelmann

1 reference

30 March 2018

Richard Dodel

13

object named as

Richard Dodel

1 reference

30 March 2018

author name string

Yaroslav Winter

2

1 reference

30 March 2018

Annika E Spottke

3

1 reference

30 March 2018

Detlef Claus

4

1 reference

30 March 2018

Christoph Grothe

5

1 reference

30 March 2018

Rolf Schröder

6

1 reference

30 March 2018

Dieter Heuss

7

1 reference

30 March 2018

Stefan Vielhaber

8

1 reference

30 March 2018

Reinhard Kiefer

10

1 reference

30 March 2018

Bertold Schrank

11

1 reference

30 March 2018

publication date

24 July 2009

1 reference

30 March 2018

published in

Journal of Neurology

1 reference

30 March 2018

volume

257

1 reference

30 March 2018

issue

1

1 reference

30 March 2018

page(s)

15-23

1 reference

30 March 2018

https://scigraph.springernature.com/pub.10.1007/s00415-009-5256-6

exact match

0 references

cites work

Incidence and prevalence of myasthenia gravis in western Denmark: 1975 to 1989.

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS00415-009-5256-6

Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS00415-009-5256-6

The economic impact of ALS.

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS00415-009-5256-6

Guidelines for pharmacoeconomic studies. Recommendations from the panel on cost effectiveness in health and medicine. Panel on cost Effectiveness in Health and Medicine

21 January 2018

1 reference

12 December 2020

Costs and quality of life of multiple sclerosis in Germany.

1 reference

12 December 2020

The economics of dying. The illusion of cost savings at the end of life

1 reference

12 December 2020

Amyotrophic lateral sclerosis severity scale

1 reference

12 December 2020

Patients with amyotrophic lateral sclerosis receiving long-term mechanical ventilation. Advance care planning and outcomes

1 reference

12 December 2020

Genetic counselling in facioscapulohumeral muscular dystrophy

1 reference

12 December 2020

Inconsistencies in the "Societal Perspective" on Costs of the Panel on Cost-Effectiveness in Health and Medicine

1 reference

12 December 2020

The costs of amyotrophic lateral sclerosis, according to type of care.

1 reference

12 December 2020

Gradients of functional ability of importance in rehabilitation of patients with progressive muscular and neuromuscular diseases

1 reference

12 December 2020

Long-term disease-related costs 4 years after stroke or TIA in Germany

1 reference

12 December 2020

Analysis of cost data in randomized trials: an application of the non-parametric bootstrap

1 reference

12 December 2020

Direct and indirect costs of refractory epilepsy in a tertiary epilepsy center in Germany.

1 reference

12 December 2020

El Escorial World Federation of Neurology criteria for the diagnosis of amyotrophic lateral sclerosis. Subcommittee on Motor Neuron Diseases/Amyotrophic Lateral Sclerosis of the World Federation of Neurology Research Group on Neuromuscular Diseases a

1 reference

12 December 2020

The cost utility analysis of riluzole for the treatment of amyotrophic lateral sclerosis in the UK.

1 reference

12 December 2020

[Empirical standard costs for health economic evaluation in Germany -- a proposal by the working group methods in health economic evaluation]

1 reference

12 December 2020

Epidemiology of amyotrophic lateral sclerosis.

1 reference

12 December 2020

The cost of a hospital ward in Europe: is there a methodology available to accurately measure the costs?

1 reference

12 December 2020

Social-economic costs and quality of life of Alzheimer disease in the Canary Islands, Spain.

1 reference

12 December 2020

1 reference

12 December 2020

Cost of illness and its predictors for Parkinson's disease in Germany

1 reference

12 December 2020

Definitive molecular diagnosis of facioscapulohumeral dystrophy

1 reference

12 December 2020

Costs and quality of life in multiple sclerosis: a cross-sectional study in the United States

1 reference

12 December 2020

Cost-of-illness analysis. What room in health economics?

1 reference

12 December 2020

Bootstrap confidence intervals: when, which, what? A practical guide for medical statisticians

1 reference

12 December 2020

ALS/MND and the perspective of health economics

1 reference

12 December 2020

10.1007/S00415-009-5256-6

Identifiers

DOI

1 reference

30 March 2018

PubMed ID

19629566

1 reference

30 March 2018